AC Immune (NASDAQ:ACIU - Free Report) - Research analysts at Leerink Partnrs increased their FY2027 earnings per share (EPS) estimates for shares of AC Immune in a research note issued to investors on Friday, July 11th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $0.13 for the year, up from their prior forecast of $0.10. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share.
AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. AC Immune had a negative return on equity of 44.60% and a negative net margin of 177.79%. The firm had revenue of $1.12 million during the quarter, compared to analysts' expectations of $1.99 million.
ACIU has been the subject of a number of other reports. HC Wainwright dropped their price target on AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Wall Street Zen raised AC Immune from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th.
Get Our Latest Stock Analysis on AC Immune
AC Immune Stock Up 0.5%
ACIU stock traded up $0.01 during midday trading on Monday, reaching $2.07. 163,418 shares of the company's stock traded hands, compared to its average volume of 142,382. The company has a 50-day simple moving average of $1.89 and a two-hundred day simple moving average of $2.12. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.26. The company has a market cap of $207.85 million, a price-to-earnings ratio of -3.57 and a beta of 1.62.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Quinn Opportunity Partners LLC bought a new position in AC Immune in the 4th quarter valued at $27,000. Two Sigma Advisers LP bought a new position in AC Immune in the 4th quarter valued at $36,000. Boothbay Fund Management LLC bought a new position in AC Immune in the 4th quarter valued at $38,000. Banque Cantonale Vaudoise bought a new position in AC Immune in the 1st quarter valued at $50,000. Finally, RPO LLC bought a new position in AC Immune in the 4th quarter valued at $51,000. 51.36% of the stock is currently owned by institutional investors.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
